

IMPORTANT CO-PAY INFORMATION



Eligibility Guidelines

To be eligible for co-pay assistance up to \$20,000 annually, patients must:

- Be prescribed RYPLAZIM for the treatment of plasminogen deficiency type I
- Be commercially insured
- Express financial need

Restrictions

- Not valid for prescriptions eligible for reimbursement by any federal or state healthcare programs, such as Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, Tricare, or any other federal or state-funded programs.
- Claims must be received within 30 days of dispense date.
- **EOBs must also be submitted within 120 days of the claim submission date.**

Enrollment Registration

The enrollment process is as easy as 1-2-3:

- 1** Scan the **QR code** to open the Medmonk RYPLAZIM Co-pay Assistance Program portal at <https://ryplazim.medmonk.com>.
- 2** If you are new to Medmonk, use the **Provider Registration** link to register your pharmacy for instant adjudication.
- 3** Use the **Provider Login** to begin the patient enrollment and eligibility check.



INDICATIONS AND USAGE

RYPLAZIM® (plasminogen, human-tvmh) is a plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

RYPLAZIM is contraindicated in patients with known hypersensitivity to plasminogen or other components of RYPLAZIM.

WARNINGS AND PRECAUTIONS:

- Bleeding: RYPLAZIM administration may lead to bleeding at active mucosal disease-related lesion sites or worsen active bleeding not related to disease lesions. Discontinue RYPLAZIM if serious bleeding occurs. Monitor patients during and for 4 hours after infusion when administering RYPLAZIM to patients with bleeding diatheses and patients taking anticoagulants, antiplatelet drugs, or other agents which may interfere with normal coagulation.

Please see additional important safety information on back and accompanying Full Prescribing Information.

GET IN TOUCH



Please contact RYPLAZIM Co-Pay Assistance with additional questions.

Customer Support: 1-866-234-3732

Customer Service Email: support@medmonk.com

Contact Kedrion Biopharma

Kedrion Biopharma Rare Disease Team

Jamie Mattern, National Rare Disease Sales Director
Email: j.mattern@kedrion.com
Cell: 609-464-1295

Frank Garcia, New England
Email: f.garcia@kedrion.com
Cell: 201-450-6813

Suzie Gennaro, Mid Atlantic
Email: s.gennaro@kedrion.com
Cell: 610-500-4869

Evan Haskins, Southeast
Email: e.haskins@kedrion.com
Cell: 551-244-5399

Alan Leerkamp, Great Lakes
Email: a.leerkamp@kedrion.com
Cell: 415-624-6735

Jen Daniel, Central
Email: j.daniel@kedrion.com
Cell: 901-849-0337

Carlos Landeros, Great Plains
Email: c.landeros@kedrion.com
Cell: 773-908-2821

Steve Haguewood, Southwest
Email: s.haguewood@kedrion.com
Cell: 201-406-7136

Lloyd White, West
Email: l.white@kedrion.com
Cell: 201-423-3659

Patricia Underland, Nurse Educator
Email: p.underland@kedrion.com
Cell: 201-401-0918

Kedrion Biopharma Customer Service

Website:



Phone: 855-353-7466

Fax: 855-751-7951

Email: kedrioncs@icsconnect.com

Hours: Monday–Friday
7:00 a.m.–7:00 p.m. CT

IMPORTANT SAFETY INFORMATION, cont.

WARNINGS AND PRECAUTIONS, cont.

- **Tissue Sloughing:** Respiratory distress due to tissue sloughing may occur in patients with mucosal lesions in the tracheobronchial tree following RYPLAZIM administration. Please monitor appropriately.
- **Transmission of Infectious Agents:** RYPLAZIM is made from human plasma and therefore carries a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob Disease (CJD) agent.
- **Hypersensitivity Reactions:** Hypersensitivity reactions, including anaphylaxis, may occur with RYPLAZIM. If symptoms occur, discontinue RYPLAZIM and administer appropriate treatment.
- **Neutralizing Antibodies:** Neutralizing antibodies (inhibitors) may develop, although they were not observed in clinical trials. If clinical efficacy is not maintained (e.g., development of new or recurrent lesions), determine plasminogen activity trough levels in plasma.
- **Laboratory Abnormalities:** Patients receiving RYPLAZIM may have elevated blood levels of D-dimer. D-dimer levels will lack interpretability in patients being screened for venous thromboembolism (VTE).

ADVERSE REACTIONS:

The most frequent (incidence $\geq 10\%$) adverse reactions in clinical trials were abdominal pain, bloating, nausea, fatigue, extremity pain, hemorrhage, constipation, dry mouth, headache, dizziness, arthralgia, and back pain.

To report SUSPECTED ADVERSE REACTIONS, contact KEDRION at 1-855-427-6378 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on front and accompanying Full Prescribing Information.